PM
RCKT icon

Prosight Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Prosight Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.39M Buy
700,000
+16,144
+2% +$53.7K 0.41% 28
2026
Q1 		$2.45M Sell
683,856
-60,086
-8% -$239K 0.4% 30
2025
Q4 		$2.61M Sell
743,942
-524,023
-41% -$1.79M 0.54% 29
2025
Q3 		$4.13M Sell
1,267,965
-312,623
-20% -$985K 0.96% 28
2025
Q2 		$3.87M Buy
1,580,588
+100,588
+7% +$510K 0.94% 28
2025
Q1 		$9.87M Buy
1,480,000
+391,294
+36% +$3.87M 3.24% 12
2024
Q4 		$13.7M Buy
1,088,706
+929,337
+583% +$14M 3.78% 12
2024
Q3 		$2.94M Buy
+159,369
New +$3.26M 0.72% 33
2023
Q1 		– Sell
-32,193
Closed -$630K – 48
2022
Q4 		$630K Sell
32,193
-167,807
-84% -$3.09M 0.34% 35
2022
Q3 		$3.19M Sell
200,000
-76,802
-28% -$1.2M 1.71% 18
2022
Q2 		$3.81M Buy
276,802
+73,534
+36% +$877K 3% 13
2022
Q1 		$3.22M Buy
203,268
+74,563
+58% +$1.29M 2.08% 15
2021
Q4 		$2.81M Buy
+128,705
New +$3.51M 1.68% 19

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Prosight Management's RCKT Position: Q2 2026 in Review

Prosight Management increased its Rocket Pharmaceuticals (RCKT) stake by 2.4% in Q2 2026, buying an estimated $53.7K and bringing the position to 700,000 shares worth $2.39M. The position accounts for 0.41% of the portfolio, ranked #28.

Prosight Management first reported a position in RCKT in Q4 2021 and has held it in 13 quarters since. The position peaked at $13.7M in Q4 2024. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Prosight Management held 700,000 shares of Rocket Pharmaceuticals worth $2.39M as of Q2 2026.
  • Prosight Management bought 16,144 Rocket Pharmaceuticals shares in Q2 2026, an estimated $53.7K.
  • Rocket Pharmaceuticals made up 0.41% of Prosight Management's portfolio in Q2 2026, its #28 holding.
  • Prosight Management first reported a position in Rocket Pharmaceuticals in Q4 2021 and has held it in 13 quarters since.
  • Prosight Management's Rocket Pharmaceuticals position peaked at $13.7M in Q4 2024.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Prosight Management's 13F filing for Q2 2026, filed 14 Aug 2026.